University of Oulu combines vibrations and nitroglycerin to clear brain proteins in trial
A clinical trial on 29 healthy adults demonstrated that whole-body vibration paired with nitroglycerin raises blood levels of Alzheimer's-related amyloid-beta.
Researchers from the University of Oulu in Finland tested a non-invasive protocol on 29 healthy adult participants without cognitive impairments to stimulate waste clearance from the brain, according to lomazoma.com lomazoma.com
lomazoma.comlomazoma.comOpen source ↗. The experimental therapy combined whole-body mechanical vibrations with a vasodilator to promote fluid dynamics through the glymphatic system. The findings were published in the journal Nature Communications.
During the trial sessions, subjects lay for nearly 40 minutes on a specialized mattress delivering whole-body vibrations at frequencies between 22 and 50 Hertz. Simultaneously, participants received sublingual nitroglycerin: two 0.5-milligram tablets administered roughly 20 minutes apart. Nitroglycerin dilates blood vessels, which researchers hypothesized would drive fluid movement through brain tissue when paired with mechanical oscillations.
Blood protein changes
Following the combined session, blood levels of three brain-derived proteins increased with statistical significance: amyloid-beta 40, amyloid-beta 42, and glial fibrillary acidic protein (GFAP). Amyloid-beta 42, a key biomarker associated with Alzheimer's disease pathology, showed an average blood concentration increase of 35 percent. Imaging scans also registered shifts in cerebrospinal fluid dynamics.
Control sessions spaced at least a week apart tested each component independently on the same cohort lomazoma.com
lomazoma.comlomazoma.comOpen source ↗. Brain scans revealed that vibration alone or nitroglycerin alone produced less than half the measured effect of the combined intervention.
Limitations and next steps
Outside researchers noted that increased systemic levels do not definitively prove accelerated brain clearance. An alternative explanation is that the protocol slows the degradation of amyloid-beta 42 in the liver. Furthermore, brain scans reflect fluid flow indirectly rather than tracing solute elimination directly.
The intervention was generally well tolerated, though six subjects reported nausea or headaches. Lead researcher Vesa Kiviniemi warned against self-experimentation due to the hypotensive risks of nitroglycerin, which can cause fainting. The team plans an upcoming trial involving 60 participants with mild cognitive impairment or Alzheimer's disease to test whether the acute effect reproduces in affected populations.
